CST6 and prostate adenocarcinoma: Patients with a higher expression of CST6 had worse survival in brain lower-grade glioma (LGG), LUAD, PAAD, PRAD, and stomach adenocarcinoma (STAD) (HR > 1 and log-rank p < 0.05, Figures 6A,B), while they indicated a favorable prognosis in KIRP, uveal melanoma (UVM), and diffuse large B-cell lymphoma (DLBC) (HR < 1 and log-rank p < 0.05, Figures 6A,B).